Who is the CEO of Akouos, Inc.?

Dr. Emmanuel Simons M.B.A., Ph.D. is a business executive who currently serves as the CEO of Akouos, Inc..

What is the Revenue Growth of Akouos, Inc.?

Revenue growth data for Akouos, Inc. is currently unavailable.

What is Akouos, Inc. operating Margin?

Akouos, Inc. operating margin is 0.00% which shows how much profit AKUS earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Akouos, Inc. operate?

Akouos, Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Akouos, Inc. revenue growth?

Revenue growth data for Akouos, Inc. is currently unavailable.

Akouos, Inc.

AKUS•NASDAQ

Healthcare

Biotechnology

$13.29

$0.00(0.00%)

Akouos, Inc. (AKUS) Stock Overview

Explore Akouos, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for AKUSStats details for AKUS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for AKUSAnalyst Recommendations details for AKUS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

CEO

Dr. Emmanuel Simons M.B.A., Ph.D.

Employees

103

Headquarters

645 Summer Street, Boston, MA

Founded

2020

Frequently Asked Questions

;